# A Study to Explore the Efficacy and Safety of Atezolizumab Plus Tiragolumab and Chemotherapy in 1st Line HER2 Negative Unresectable, Recurrent or Metastatic Gastric Cancer or Adenocarcinoma of Gastroesophageal Junction (GEJ)

> **NCT04933227** · PHASE2 · TERMINATED · sponsor: **Hoffmann-La Roche** · enrollment: 29 (actual)

## Conditions studied

- Stomach Neoplasms
- Gastric Cancer
- Gastroesophageal Junction Adenocarcinoma

## Interventions

- **DRUG:** Atezolizumab
- **DRUG:** Tiragolumab
- **DRUG:** Oxaliplatin
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT04933227
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-08-06
- **Primary completion:** 2023-11-17
- **Final completion:** 2023-11-17
- **Target enrollment:** 29 (ACTUAL)
- **Why stopped:** Sponsor's decision to terminate the study after Stage 1; will not proceed with Stage 2.
- **Last updated:** 2024-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04933227

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04933227, "A Study to Explore the Efficacy and Safety of Atezolizumab Plus Tiragolumab and Chemotherapy in 1st Line HER2 Negative Unresectable, Recurrent or Metastatic Gastric Cancer or Adenocarcinoma of Gastroesophageal Junction (GEJ)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04933227. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*